|
| 產(chǎn)地 | 進(jìn)口、國產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號(hào) | CS11394 |
| 應(yīng)用范圍 | ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 |
| CAS編號(hào) | |
| 抗體名 | Anti-SRCAP |
| 克隆性 | |
| 靶點(diǎn) | 詳見說明書 |
| 適應(yīng)物種 | 詳見說明書 |
| 形態(tài) | 詳見說明書 |
| 宿主 | 詳見說明書 |
| 亞型 | IgG |
| 標(biāo)識(shí)物 | 詳見說明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from human SRCAP |
抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：
1. 轉(zhuǎn)綠激活蛋白SRCAP抗體規(guī)格 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來篩選最適條件；
3.用NHSB量過量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等；
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性；
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價(jià)結(jié)合；
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；
8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細(xì)胞可導(dǎo)致高本底。
產(chǎn)品訂購信息：
英文名稱 Anti-SRCAP
中文名稱 轉(zhuǎn)綠激活蛋白SRCAP抗體規(guī)格
別 名 DOMO1; EAF1; Helicase SRCAP; Snf2 related CBP activator protein; SWR1; SRCAP_HUMAN.
濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Dog, Pig, Cow, Rabbit, Sheep
產(chǎn)品類型 一抗
研究領(lǐng)域 細(xì)胞生物 神經(jīng)生物學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 表觀遺傳學(xué)
蛋白分子量 predicted molecular weight: 343kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human SRCAP
亞 型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
轉(zhuǎn)綠激活蛋白SRCAP抗體規(guī)格 產(chǎn)品應(yīng)用 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 SRCAP (Snf2-related CREBBP activator protein), also known as EAF1, SWR1, or DOMO1, is a 3,230 amino acid protein that belongs to a family of helicases and contains one HSA domain, one helicase C-terminal domain, one helicase ATP-binding domain and three A.T hook DNA-binding domains. Localized to the nucleus, SRCAP functions as a catalytic component of the SRCAP complex, a multi-protein structure that mediates the ATP-dependent exchange of histone dimers for nucleosomal histones, an event that regulates the transcription of select genes via chromatin remodeling. Additionally, the SRCAP complex acts as a coactivator for steroid receptor-mediated transcription, Notch-mediated transcription and CREB-mediated transcription. SRCAP is expressed as multiple alternatively spliced isoforms and is subject to DNA damage-dependent phosphorylation by ATM or ATR.
Function : Catalytic component of the SRCAP complex which mediates the ATP-dependent exchange of histone H2AZ/H2B dimers for nucleosomal H2A/H2B, leading to transcriptional regulation of selected genes by chromatin remodeling. Acts as a coactivator for CREB-mediated transcription, steroid receptor-mediated transcription, and Notch-mediated transcription (from SwissProt).
Subunit : Interacts with CREBBP and EP300. May be part of a complex containing SRCAP, CREBBP, CARM1 and GRIP1. Component of the chromatin-remodeling SRCAP complex composed of at least SRCAP, DMAP1, RUVBL1, RUVBL2, ACTL6A, YEATS4, VPS72, ACTR6 and ZNHIT1. Component of a NuA4-related complex which contains EP400, TRRAP/PAF400, SRCAP, BRD8/SMAP, EPC1, DMAP1/DNMAP1, RUVBL1/TIP49, RUVBL2, actin, ACTL6A/BAF53A, VPS72 and YEATS4/GAS41. Interacts with hepatitis C virus (HCV) NS5A and human adenovirus 2 DBP.
Subcellular Location : Nuclear
Post-translational modifications : Phosphorylated upon DNA damage, probably by ATM or ATR.
DISEASE : Defects in SRCAP are the cause of Floating-Harbor syndrome (FLHS) [MIM:136140]. A rare genetic disorder characterized by proportionate short stature, delayed bone age, delayed speech development, and typical facial features. The face is triangular with deep-set eyes, long eyelashes, bulbous nose, wide columella, short philtrum, and thin lips.
Similarity : Belongs to the SNF2/RAD54 helicase family. SWR1 subfamily.
Contains 3 A.T hook DNA-binding domains.
Contains 1 helicase ATP-binding domain.
Contains 1 helicase C-terminal domain.
Contains 1 HSA domain.
Database links : UniProtKB/Swiss-Prot: Q6ZRS2.3
抗體的鑒定：
1）轉(zhuǎn)綠激活蛋白SRCAP抗體規(guī)格 抗體的效價(jià)鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力?？贵w的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗(yàn)測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測定對抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。
Anti-Phospho-Stat2 (Tyr690)/FITC 熒光素標(biāo)記磷酸化信號(hào)轉(zhuǎn)導(dǎo)和轉(zhuǎn)錄激活因子2抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Ang- II (Angiotensin II ) 緊張素II抗原Multi-class antibodies規(guī)格： 0.5mg
磷脂酰肌醇激酶抗體 Anti-PI3K/P85 alpha 0.1ml
14-3-3 Tau 英文名稱： 14-3-3τ蛋白抗體 0.1ml
EGFR 英文名稱： 表皮生長因子受體抗體 0.1ml
Rhesus antibody Rh phospho-MYL9(Thr19) 磷酸化肌球蛋白輕鏈9抗體 規(guī)格 0.1ml
Ang- II (Angiotensin II ) 緊張素II抗原Multi-class antibodies規(guī)格： 0.5mg
Anti-TRAF1/FITC 熒光素標(biāo)記壞死因子受體相關(guān)因子1抗體IgGMulti-class antibodies規(guī)格： 0.2ml
PSD-95 突觸后密度蛋白95(抗原)Multi-class antibodies規(guī)格： 0.5mg
壞死因子受體相關(guān)因子6抗體 Anti-TRAF6 0.2ml
SPRR3 英文名稱： 角質(zhì)蛋白β抗體 0.2ml
ELAVL2 英文名稱： ELAVL2蛋白抗體 0.2ml
Rhesus antibody Rh phospho-IRS1(Tyr895) 磷酸化受體底物-1抗體 規(guī)格 0.1ml
PSD-95 突觸后密度蛋白95(抗原)Multi-class antibodies規(guī)格： 0.5mg
ROCK1 (Rho-associated coiled-coil containing protein kinase 1) Rho相關(guān)蛋白激酶1抗原Multi-class antibodies規(guī)格： 0.5mg
Anti-Phospho-Bad(Ser112) 磷酸化相關(guān)死亡促進(jìn)因子抗體Multi-class antibodies規(guī)格： 0.1ml
Rhesus antibody Rh PHKA1 磷酸激酶α1抗體 規(guī)格 0.2ml
Keratin6 濃縮液 0.1ml 進(jìn)口分裝
URAT1/SLC22A11 英文名稱： 尿酸鹽重吸收轉(zhuǎn)運(yùn)子1抗體 0.1ml
Phospho-CD18 (Thr758) 英文名稱： 磷酸化整合素β2/Integrin β2抗體 0.1ml
Anti-Phospho-Bad(Ser112) 磷酸化相關(guān)死亡促進(jìn)因子抗體Multi-class antibodies規(guī)格： 0.1ml
LIF Protein Mouse 重組小鼠 LIF 蛋白 (Fc 標(biāo)簽)
小鼠肝竇內(nèi)皮細(xì)胞完全培養(yǎng)基 100mL
IgG2a Others Mouse 小鼠 IgG2a-Fc 人細(xì)胞裂解液 (陽性對照)
RAG小鼠腎腺癌細(xì)胞 RAG mice renal adenocarcinoma cells MEM培養(yǎng)基(GIBCO)+10%FBS
CL-0103Hep G2(人細(xì)胞)5×106cells/瓶×2
RTE(大鼠氣管上皮細(xì)胞) 5×106cells/瓶×2 A375(人類惡性)
CM-M087小鼠軟骨細(xì)胞完全培養(yǎng)基100mL
IL2RB Others Mouse 小鼠 CD122 / IL2RB / IL2 Receptor beta 人細(xì)胞裂解液 (陽性對照)
動(dòng)物上皮細(xì)胞培養(yǎng)基EpiCM-a-prf
NCI-H1299細(xì)胞，人細(xì)胞 人胚腎上皮細(xì)胞,HK-2C細(xì)胞 真皮微內(nèi)皮細(xì)胞Many types of cells包裝：5 × 105次方(1ml)
豬腎細(xì)胞;LLC-PK1
PRSS8 Others Human 人 Prostasin / Prss8 人細(xì)胞裂解液 (陽性對照)
轉(zhuǎn)綠激活蛋白SRCAP抗體規(guī)格 LIF Protein Mouse 重組小鼠 LIF 蛋白 (Fc 標(biāo)簽)
小鼠肝竇內(nèi)皮細(xì)胞完全培養(yǎng)基 100mL
IgG2a Others Mouse 小鼠 IgG2a-Fc 人細(xì)胞裂解液 (陽性對照)
RAG小鼠腎腺癌細(xì)胞 RAG mice renal adenocarcinoma cells MEM培養(yǎng)基(GIBCO)+10%FBS
CL-0103Hep G2(人細(xì)胞)5×106cells/瓶×2
RTE(大鼠氣管上皮細(xì)胞) 5×106cells/瓶×2 A375(人類惡性)
|
|
|
|
